Tivic Health reports Q1 net loss down 29% YoY; raises $4M in May offering

Valion Bio, Inc.

2024-Q1 EPS reported -$1.01 revenue$334,000

Q1 revenue $334K (-11% YoY), net loss $1.5M vs $2.1M, operating expenses down 26%.
Gross margin improved to 50% from 30%; gross profit up 48% to $167K.
May 13 public offering: 4.71M shares + warrants at $0.85/share, gross $4M, net $3.5M.
Clinical study with Feinstein Institutes showed ncVNS induced autonomic and neurologic responses equivalent to implanted devices.
Launched ClearUP 2.0; exclusive distribution deal with top-10 distributor for Walmart, Target, Kroger.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Valion Bio, Inc. reported first quarter 2024 results: revenue $334 thousand.

Period: first quarter 2024
Revenue: $334 thousand
Result: reported results

Exact text from the filing

Revenue for Q1 2024 was $334 thousand, compared to $376 thousand for Q1 2023, a decrease of $42 thousand, or 11%, due reduced unit sales volume offset by increased selling price.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-060486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.